Quick-Med, Foster complete joint development program for NIMBUS antimicrobial catheters

Quick-Med Technologies, Inc. (OTCBB:QMDT) announced today that it has successfully completed its joint development program with Foster Corporation, a member of PolyMedex Discovery Group, to collaborate in applying Quick-Med's proprietary NIMBUS^® technology to thermoplastics for catheters and other medical product applications.

"Completion of our development work with Foster to incorporate our non-leaching, highly effective NIMBUS antimicrobial technology in catheters represents a key milestone for Quick-Med," said J. Ladd Greeno, CEO of Quick-Med Technologies. "By design, a NIMBUS antimicrobial catheter is far more advanced than any other antimicrobial catheter on the $14 billion market because the active antimicrobial molecule is integrated into the device and will not migrate into surrounding tissue or engender bacterial resistance."

Catheter-associated urinary tract infection is the most common nosocomial infection. Each year, urinary catheters are inserted in more than 5 million patients in U.S. acute-care hospitals and extended-care facilities. More than 1 million of those patients acquire a catheter-associated urinary tract infection. When infection occurs, the potential medical and economic consequences can be tremendous, including increased mortality and significant additional heath care costs.

What makes NIMBUS different from any other antimicrobial technology is its permanent bond and its ability to be effective even in the presence of large amounts of serum and body fluids, a critical consideration with products inserted into the body. The active agent is permanently bonded to the substrate, keeping the biocide from depletion, while killing microbes (such as MRSA, VRE, and many others) that are present on the device. NIMBUS has an excellent safety record, in comparison to the well-documented toxic effects of silver-based antimicrobials.